COMMUNIQUÉS West-GlobeNewswire
-
Kairos Pharma Closing of $6.2 Million Initial Public Offering
17/09/2024 - 22:29 -
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16/09/2024 - 14:30 -
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
16/09/2024 - 14:30 -
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16/09/2024 - 14:30 -
BAMF Health Announces Strategic Clinical Trials Partnership with Adaptive Research
16/09/2024 - 14:30 -
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
16/09/2024 - 14:30 -
Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients
16/09/2024 - 14:30 -
NeuroStar® Releases Software Upgrades to Elevate Patient Care
16/09/2024 - 14:32 -
Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
16/09/2024 - 14:45 -
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16/09/2024 - 14:45 -
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
16/09/2024 - 14:53 -
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
16/09/2024 - 15:00 -
London Man Grateful to Doctors Who Treated Rare Flesh-Eating Disease, Pledges $25,000
16/09/2024 - 15:00 -
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
16/09/2024 - 15:00 -
Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy
16/09/2024 - 15:00 -
Novo Nordisk A/S - share repurchase programme
16/09/2024 - 15:15 -
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
16/09/2024 - 15:31 -
Thought Leadership & Innovation Foundation Announces Gala to Initiate Development of Patient Portal for Age-Related Macular Degeneration
16/09/2024 - 16:00 -
WellRithms Featured for Fourth Consecutive Year on Portland Business Journal List of Fastest-Growing Private Companies
16/09/2024 - 16:00
Pages